Leslie M. Shaw, PhD

Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Director, Clinical Toxicology Laboratory
University of Pennsylvania Perelman School of Medicine

Contact InformationHospital of the University of Pennsylvania
7.103 Founders Pavilion
3400 Spruce Street
Philadelphia, PA 19104
Office: (215) 662-6575
Fax: (215) 662-7529


Specialty Division

Laboratory Medicine

Research Expertise

Development, validation and implementation of neurodegenerative diseases biomarkers in cerebrospinal fluid and plasma into treatment trials and clinical studies (eg, ADNI study; UPENN ADRC; PPMI study). These studies include the use of manual and highly automated immunoassays and for amyloid beta(1-42), U-p53AZ and for total tau the use of high sensitivity UPLC/tandem mass spectrometry. Multi-modal statistical analyses of these study data to address several questions including the diagnostic utilities of these biomarkers; assessments of the longitudinal trajectories of these biomarkers in AD, MCI and cognitively normal controls to assess the neuropathological changes over time in these individuals.

Clinical Expertise

Measurement and interpretation of the toxicokinetics of drugs and toxins in patients affected by them. Interpretation of the pharmacokinetics of immunosuppressant maintenance medications in transplant patients.

Other Expertise

Development and implementation of mass spectrometry-based methods for measuring small molecules of clinical utility including therapeutic drugs, toxins and special chemistry tests including Xylazine; 25-OH vitamin D; and biologicals, eg, Infliximab.


B.S. (Cum Laude, Chemistry), LeMoyne College, Syracuse, New York, 1962
Ph.D. (Biochemistry), S.U.N.Y. at Upstate Medical Center, 1968

Specialty Certification

American Board of Clinical Chemistry, 1973
American Board of Clinical Chemistry in Toxicological Chemistry, 1990
USC School of Medicine, Laboratory of Applied Pharmacokinetics, 1995

Postgraduate Training

NIH Post doctoral Fellowship Department of Molecular Biology, The Johns Hopkins University, Baltimore, MD, 1968-1970
Fellow, Neuroscience Research Program, 1969-1969
NIH Postdoctoral Fellowship, William Pepper Laboratories, Hospital of the University of Pennsylvania, Philadelphia, PA, 1970-1972

Awards and Honors

Norman Kubasik Lectureship Award, Upstate New York AACC Meeting, 1992-1992
Outstanding Speaker Award, 1995, 1996, 1997, 2000, 2001, 2002, 2003, American Association for Clinical Chemistry, 1995-2003
Reinhold Award, Philadelphia Section, AACC, 1995-1995
IATDMCT Charles Pippenger Award for Outstanding Contributions in Therapeutic Drug Monitoring, 1999-1999
The Peter C Nowell Teaching Award, University of Pennsylvania Medical Center, 1999-1999
The Kevin Salhany, MD, Award for Excellence in Clinical Teaching; Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, 2005-2005
LeMoyne College - Distinguished Alumni Award, 2012-2012
AACC Lifetime Achievement Award in Clinical Chemistry and Laboratory Medicine., 2013

Memberships and Professional Organizations

Alpha Sigma Nu, National Jesuit Honor Society, 1962 - 1964
American Chemical Society, 1962 - present
American Association for Clinical Chemistry, 1972 - present
Philadelphia Section, American Association for Clinical Chemistry:, 1978 - Present
Philadelphia Section, American Association for Clinical Chemistry: 1996 (Program Chairman).
Philadelphia Section, American Association for Clinical Chemistry: 1978, 1978 - Present
American Association for the Advancement of Science, 1978 - present
International Federation of Clinical Chemistry, 1979 - present
AACC/NACB Task Force on Cyclosporine Monitoring, 1985 - 1987
National Academy of Clinical Biochemistry:, 1986 - present
International Association for Therapeutic Drug Monitoring and Clinical Toxicology, 1989 - present
American Society for Mass Spectroscopy, 1991 - 1994
Therapeutic Drug Monitoring and Clinical Toxicology Division of the AACC:, 1991 - Present
USP Council of Experts,, 2001 - 2002
Society of Toxicology, 2004 - 2007, 2004 - 2007
Alzheimers Association, 2005 - Present
Eli Lilly, 2011 - 2018
Alzheimers Association Global Biomarker Standardization Consortium., 2011 - Present
Roche (Member of Scientific Advisory Board), 2016 - Present
FNIH Biomarker Consortium, plasma abeta project team, 2017 - ongoing
Cerebrospinal Fluid appropriate Use, Criteria Workgroup, Alzheimers Association., 2017 - 2018
FNIH Biomarker Consortium Plasma Aβ Project Team., 2022 - Present

Selected Publications

Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity.

Zicha S, Bateman RJ, Shaw LM, Zetterberg H, Bannon AW, Horton WA, et al., Alz Dementia, 2022

Validation of Plasma Amyloid-β42/40 for Detecting Alzheimer Disease Amyloid Plaques

Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, Shaw LM, Masters CL, Fowler CJ, Trojanowski JQ, Korecka M, Martins RN, Janelidze S, Hansson O, Bateman RJ., Neurology. 98(): e688 - e699, 2022

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer’s disease: an international overview.

Dalaby C, Teunissen CE, Blennow K, Alcolea D, Arisi I, Amar EB, …Shaw LM,…Lehman S., Alzheimer’s and Dementia., 2022

State-of-the-Art of lumbar puncture and its place in the journey of patients with Alzheimer’s disease.

Hampel H, Shaw LM, Aisen P, Chen C, Lleo A, Iwatsubo T, Iwata A, Yamada M, Ikeuchi T, Jia J, Wang H, Teunissen CE, Peskind E, Blennow K, Cummings J, Vergallo A., Alzheimer’s and Dementia. 18(): 159 - 177 , 2022

Elevated plasma phosphorylated tau 181 in amyotrophic lateral sclerosis relates to lower motor neuron dysfunction.

Cousins KAQ, Shaw LM, Shellikeri S, Dratch L, Rosario L, Elman LB, et al., Ann Neurol 2022, 2022

ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration.

Cousins KAQ, Phillips JS, Irwin DJ, Lee EB, Wolk DA, Shaw LM, Zetterberg H, Blennow K, Burke SE, Kinney NG, Gibbons GS, McMillan CT, Trojanowski JQ, Grossman M., Alzheimer's & Dementia. 17 (5)(): 822 - 30, 2021

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.

Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Suarez-Calvet M, Saha-Chaudhuri P, Lussier F, Kvartsberg H, Rial AM, Pascoal TA, Andreasson U, Scholl M, Weiner MW, Rosa-Neto P, Trojanowski JQ, Shaw LM, Blennow K, Zetterberg H, Alzheimer's Disease Neuroimaging Initiative., Molecular Psychiatry. 26 (2) (): 429 - 442, 2021

Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease.

Libiger O, Shaw LM, Watson MH, Nairn AC, Umana KL, Biarnes MC, Canet-Aviles RM, Jack CR Jr, Breton YA, Cortes L, Chelsky D, Spellman DS, Baker SA, Raghavan N, Potter WZ, Alzheimer's Disease Neuroimaging Initiative (ADNI), Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, Longitudinal CSF Proteomics Project Team., Alzheimer's & Dementia. 17 (12)(): 1976 - 87, 2021

Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.

Moon S, Kim S, Mankhong S, Choi SH, Vandijck M, Kostanjevecki V, Jeong JH, Yoon SJ, Park KW, Kim EJ, Yoon B, Kim HJ, Jang JW, Hong JY, Park DH, Shaw LM, Kang JH., Alzheimer's Research & Therapy. 13 (1) (): 22, 2021

Postoperative pulmonary complications following major head and neck cancer surgery.

Shaw LM, Iseli TA, Wiesenfeld D, Ramakrishnan A, Granger CL., International Journal of Oral & Maxillofacial Surgery. 50 (3) (): 302 - 8, 2021